{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006678","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.337973+00:00","generated_at":"2026-06-09T01:31:20.969663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anika Q3 revenue $41.5M (+3% YoY); raises FY2023 guidance to $164-166M","bullets":["Revenue $41.5M (+3% YoY); Joint Preservation & Restoration up 14% to $13.5M, OA Pain Mgmt up 2% to $24.9M.","Net loss ($6.6M), ($0.45)/share; adjusted net income $0.00/diluted share; includes $4.2M software charge.","Adjusted EBITDA $4.7M vs $4.1M; cash from ops $6.5M, cash $70.7M.","Raised FY2023 revenue guidance to $164-166M (from $159.5-163M), implying 5-6% growth.","FDA cleared Integrity Implant System (rotator cuff patch) and X-Twist biocomposite; launches Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006678","json":"https://secwatch.observer/filing/0001171843-23-006678.json","markdown":"https://secwatch.observer/filing/0001171843-23-006678.md","text":"https://secwatch.observer/filing/0001171843-23-006678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184323006678/0001171843-23-006678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184323006678/f8k_110223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:31:20.969663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b182da7a046e21cd9e39f062b34f3db5b1d7109","claim":"Anika Therapeutics, Inc. updated its the third quarter ended September 30, 2023 guidance (raised).","evidence_excerpt":"On November 2, 2023, Anika Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323006678/0001171843-23-006678-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}